The rising prevalence of fibrotic diseases, such as idiopathic pulmonary fibrosis, hepatic cirrhosis, and renal fibrosis, is a significant driver of the Global Fibrotic Diseases Treatment Market. Factors such as aging populations, lifestyle changes, and increasing rates of chronic conditions like diabetes and hypertension are contributing to a higher incidence of these diseases. As the number of affected individuals grows, the demand for effective treatments intensifies, driving the need for advanced therapies, including antifibrotic drugs and biologics. Healthcare systems face growing pressure to manage chronic fibrotic conditions, driving demand for more effective treatments and fueling market growth.
Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/global-fibrotic-diseases-treatment-market
Data Bridge Market Research analyzes that the Global Fibrotic Diseases Treatment Market is expected to reach USD 10.35 billion by 2032 from USD 5.79 billion in 2024, growing with CAGR of 7.6% during forecast period of 2025 to 2032.
Key Findings of the Study
Technological Advancement in the Treatment of Fibrosis Diseases
Innovations such as the development of biologic therapies, gene editing technologies, and targeted antifibrotic drugs have significantly improved the efficacy of treatments. New diagnostic tools, including advanced imaging and biomarker-based tests, allow for earlier detection and more personalized treatment plans, enhancing patient outcomes. Additionally, improvements in drug delivery systems, such as extended-release formulations and inhalable therapies, offer better convenience and effectiveness.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2025 to 2032
|
|
Base Year
|
2024
|
|
Historic Year
|
2023 (Customizable to 2013–2017)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Treatment (Medication, Organ Transplantation, Oxygen Therapy, and Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, and Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, and Others)
|
|
Countries Covered
|
U.S, Canada, Mexico, Dominican Republic, Jamaica, Panama, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Ecuador, Chile, Colombia, Venezuela, Argentina, Peru, Curaçao, Paraguay, Uruguay, Trinidad And Tobago, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Israel, Bahrain, and Rest of Middle East and Africa
|
|
Market Players Covered
|
C.H. Boehringer Sohn AG & Co. KG. (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Sandoz International GmbH (Germany), Accord Healthcare (U.K.), AbbVie Inc. (U.S.), Redx Pharma Pic (U.K.), Bristol-Myers Squibb Company (U.S.), BioMX (U.S.), KITHER BIOTECH S.R.L. (Italy), Verona Pharma pic (U.K.), Intercept Pharmaceuticals, Inc. (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand.
|
Segment Analysis
Global fibrotic diseases treatment market is segmented into three notable segments based on treatment, and application.
- Based on treatment, the market is segmented into medication, organ transplantation, oxygen therapy, and others
In 2025, the medication segment of the treatment is expected to dominate the global fibrotic diseases treatment market
In 2025, the medication segment is expected to dominate the market with a market share of 85.12%, due to the medication segment is expected to dominate the market due to the increasing availability of effective anti-fibrotic drugs
- Based on application, the market is segmented into idiopathic pulmonary fibrosis, hepatic cirrhosis, renal fibrosis, cutaneous fibrosis, and others
In 2025, the idiopathic pulmonary fibrosis segment is expected to dominate the global fibrotic diseases treatment market
In 2025, the idiopathic pulmonary fibrosis segment is expected to dominate the market with a market share of 42.82%, due to growing preference for non-invasive treatment options
- Based on end user, the market is segmented into hospitals, specialty clinics, academic and research institutes, and others. In 2025, the hospitals segment is expected to dominate the market with a market share of 48.80%
Major Players
Data Bridge Market Research analyses C.H. Boehringer Sohn AG & Co. KG.(Germany), F. Hoffmann-La Roche Ltd (Switzerland), Teva Pharmaceutical Industries Ltd.(Israel), Sandoz International GmbH (Germany), Accord Healthcare (U.S.) as major market players in this market.
Market Development
- In July 2024, Teva and Sanofi announced an updated timeline for the anti-TL1A program, duvakitug, a monoclonal antibody targeting TL1A for moderate-to-severe IBD. Advancing this program strengthens both companies’ positions in the IBD treatment market, potentially expanding their offerings in immunology
- In November 2022, Sandoz International GmbH, a global leader in generic and biosimilar medicines, today announced an additional investment of EUR 50 million to support increased European manufacturing capacity for finished dosage form (FDF) penicillins, the leading class of antibiotics worldwide. This has helped the company to expand globally
- In September, 2024 Boehringer Ingelheim International GmbH announced that the FIBRONEER-IPF trial met its primary endpoint of FVC improvement at week 52, and it plans to submit a new drug application for nerandomilast for IPF treatment to the FDA and other global authorities. This successful trial and upcoming submission will strengthen Boehringer Ingelheim’s position in the competitive IPF market, potentially expanding its respiratory drug portfolio
Regional Analysis
Geographically, the countries covered in the global fibrotic diseases treatment market report are U.S, Canada, Mexico, Dominican Republic, Jamaica, Panama, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Taiwan, rest of Asia-Pacific, Brazil, Ecuador, Chile, Colombia, Venezuela, Argentina, Peru, Curaçao, Paraguay, Uruguay, Trinidad And Tobago, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Israel, Bahrain, and rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is expected to dominate in global fibrotic diseases treatment market
North America is expected to dominate the market due to the high prevalence of chronic fibrotic conditions, strong healthcare infrastructure, extensive R&D activities.
Asia-Pacific is fastest growing region in the global fibrotic diseases treatment market
Asia-Pacific is the fastest growing region in the global fibrotic diseases treatment market due to rising healthcare investments and improving access to advanced therapies. Additionally, growing awareness and supportive government initiatives further drive market growth.
For more detailed information about the global fibrotic diseases treatment market report, click here – https://www.databridgemarketresearch.com/pt/reports/global-fibrotic-diseases-treatment-market
